Log In or Register to Join The Conversation!
  • This topic has 1 voice and 0 replies.
Viewing 0 reply threads
  • Author
    • #13683

      The Cystic Fibrosis Foundation (CFF) is giving Eloxx Pharmaceuticals up to $1.61 million to support its planned Phase 2 clinical trial program assessing the safety, tolerability, and chemical properties of ELX-02, Eloxx’s lead investigational compound to treat cystic fibrosis (CF) caused by nonsense, or stop, mutations.

      The program is set to include two open-label, dose escalation, Phase 2 trials. One, called EL-012, will enroll up to eight patients in the U.S.; the other, EL-004, will enroll up to 16 patients in Europe. Click here to learn more about it.

      What do you think of this research?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Copyright © 2017-2020 All rights reserved.

©2020 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?


Create Account